Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 5
More JCP Articles
Original Research
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
July 7, 2025
The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
Original Research
Differentiating Subtypes of MDD Using Serum Biomarkers
June 23, 2025
Significant differences in biomarker profiles were observed across MDD subtypes: the melancholic subtype showed higher cortisol levels and lower serotonin levels, and the atypical subtype showed elevated levels of…
Original Research
Bright Light Therapy in the Morning or Midday for Nonseasonal Depression in Bipolar Disorder
June 23, 2025
Bright light therapy is well tolerated in bipolar disorder, starting at 45 minutes/day, with only 6% of patients experiencing a hypomanic switch and 13% experiencing subsyndromic symptoms, which resolved…
Original Research
Association Between Adult Sexual Assault and Psychiatric Disorders: Results From NESARC
June 16, 2025
Among participants who experienced adult sexual assault, 85.25% had at least 1 lifetime psychiatric disorder. In women, the strongest associations were with PTSD, borderline personality disorder, and suicide attempts,…
Clinical and Practical Psychopharmacology
Schizophrenia, Antipsychotic Drugs, and Risk of Breast Cancer
June 16, 2025
This article examines recent meta-analyses and observational studies on breast cancer risk in women with schizophrenia, especially in the context of treatment with first generation and second generation antipsychotics
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
June 13, 2025
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
